Tech Company Financing Transactions
Frontier Medicines Funding Round
On 6/27/2019, Frontier Medicines landed $67 million in Series A funding from Deerfield Capital, DROIA and MPM Capital.
Transaction Overview
Company Name
Announced On
6/27/2019
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series A
Investors
Proceeds Purpose
The Series A financing will enable Frontier Medicines to invest in research and development, talent acquisition and advancement of its platform and therapeutic programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 2nd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn't found a way to treat (or drug) with pharmaceutical interventions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Varma
Chief Financial Officer
Gregory Chow
Chief Scientific Officer
Kevin Webster
Chief Technical Officer
Johannes Hermann
Co-Founder
Daniel Nomura
Co-Founder
Roberto Zoncu
Vice President
Daniel Erlanson
Browse more venture capital transactions:
Prev: 6/27/2019: Showpad venture capital transaction
Next: 6/27/2019: Venn venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs